Urinalysis Market size to exceed $5.2bn by 2028

Urinalysis Market size is set to surpass USD 5.2 billion by 2028, according to a new research report by Global Market Insights Inc.
 

Rising incidence rate of urinary tract infection (UTIs) in women coupled with several awareness programs organized by the government authorities is driving the industry expansion. For instance, the Public Health Ontario of the Ontario Agency for Health Protection and Promotion have developed Urinary Tract Infection (UTI) program aimed to respond various concerns regarding the overconsumption of antibiotics for presumed UTIs among residents across long-term care homes (LTCHs). Such initiatives broaden public awareness regarding appropriate diagnosis and treatment of UTI that will accelerate the urinalysis market revenue.
 

The growing prevalence of various chronic conditions including cardiovascular diseases and diabetes along with several other risk factors are contributing to the existing burden of chronic kidney diseases (CKDs). Further, other health conditions such as high blood pressure, hypertension, post procedural complications of urinary catheterization and vascular diseases are significantly adding to the incidence rate of chronic renal diseases. Thus, increasing need for urinalysis with rising patient population owing to the aforementioned factors is expected to propel the market outlook.
 

Urinalysis market continued to witness considerable revenue growth amid COVID-19 pandemic. As the guidelines for hospitalized COVID-19 patients suggested urinalysis for the detection of SARS-CoV-2 renal tropism, the industry experienced increased demand for testing in healthcare facilities. Furthermore, the patients recovered from the infection were recommended to visit nephrologists at intervals to avoid further associated health complications. Thus, the COVID-19 has positively impacted the overall industry demand.
 

Consistent demand for urinalysis consumables will foster the market trends

Consumables segment exceeded USD 2.3 billion in 2021. The segment is further classified into dipsticks, reagents, and disposables. This is attributable to frequent purchase in comparison with instruments across healthcare facilities as well as home settings. As some consumables are disposable products and are not indicated for repetitive usage, the professionals or patients are required to purchase those products for every single testing. This leads to higher product sales.
 

Additionally, various benefits associated with urinalysis consumables including dipsticks such as reduced time for results allowing effective clinical management, easy availability, accessibility at home settings and cost-effectiveness will positively impact the industry landscape.
 

Browse key industry insights spread across 170 pages with 283 market data tables & 16 figures & charts from the report, “Urinalysis Market Analysis By Product (Consumables {Dipsticks, Reagents, Disposables}, Instruments {Biochemical Urine Analyzers, Automated Urine Sediment Analyzers}), Application (Urinary Tract Infections [UTI], Kidney Diseases, Pregnancy, Diabetes), End-use (Clinical Laboratories, Hospitals, Home Healthcare), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2028” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/urinalysis-market
 

Growing demand for urine sample examination among diabetes patients will accelerate the market progression

Based on application, the urinalysis market is classified into urinary tract infections (UTI), kidney diseases, pregnancy, diabetes, and others. The diabetes segment is forecast to proceed at 8.1% CAGR during the analysis timeframe. Among the diabetic population, the urine tests are frequently performed for the analysis of ketones in the urine to evaluate severe hyperglycemia. Thus, the higher disease prevalence rate will ultimately influence the demand for urinalysis.
 

For instance, as per the data by the International Diabetes Federation, the diabetes population across the globe is estimated to reach 552 million by 2030 from 366 million in 2011. As prolonged diabetes poses higher risk of kidney and liver disorders, the market will foresee escalating demand for urinalysis among patient population.
 

Availability of automated instruments in hospitals to cater increasing urinalysis demand in settings

The urinalysis market based on end-use is categorized into clinical laboratories, hospitals, home healthcare and others. The hospital segment was accounted for more than 38% market share in 2021 and is estimated witness considerable CAGR during the forecast timeframe due to increasing demand for urine tests in settings. Preference for urinalysis as primary diagnosis for range of diseases by healthcare professionals in hospitals will propel the market share.
 

Moreover, availability of advanced equipment including automated urine analyzers for accurate diagnosis in these facilities coupled with presence of skilled workforce will benefit the segment. Further, need to assess history of kidney diseases or UTI among patients undergoing surgeries in hospitals will positively impact the urinalysis testing volume in settings.
 

Government support for R&D in the European countries will offer unprecedented growth opportunities

Europe urinalysis market is projected to progress at 5.1% CAGR during the analysis timeframe. Increasing focus on R&D with government funding will lead to the market progression in the region. For instance, the researchers developed Medipee, an in-home urinalysis device with the help of the EU-funding. The device is designed to provide accurate in-home diagnosis with the monitoring of hydration levels and assist in detection of potential health concerns. Thus, focus of research centres and industry players on such innovations in European region will impel the regional market statistics.
 

Collaborative efforts by the market participants will provide them sustainable competitive advantage

Some of the prominent market players operating in the urinalysis industry include Sysmex Corporation, F. Hoffmann-La Roche Ltd, ACON Laboratories, Cardinal Health, Abbott, Bio-Rad Laboratories Inc., ARKRAY Inc., Erba Mannheim, Siemens Healthineers, 77 Elektronika Kft, and Teco Diagnostics among others. These market participants are involved in strategic partnerships, collaborations, agreements, and mergers to strengthen their market position.
 

For instance, in August 2020, Siemens Healthineers announced an exclusive agreement with Sysmex America, Inc. for distribution and related services of its CLINITEK Novus Automated Urine Analyzer used in hospital settings and reference laboratories across the North America. This has enhanced development capabilities as well as customer reach of both the firms.